Publication

Application of PET Tracers in Molecular Imaging for Breast Cancer

Boers, J., de Vries, E. F. J., Glaudemans, A. W. J. M., Hospers, G. A. P. & Schröder, C. P., 6-Jul-2020, In : Current oncology reports. 22, 8, 16 p., 85.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Boers, J., de Vries, E. F. J., Glaudemans, A. W. J. M., Hospers, G. A. P., & Schröder, C. P. (2020). Application of PET Tracers in Molecular Imaging for Breast Cancer. Current oncology reports, 22(8), [85]. https://doi.org/10.1007/s11912-020-00940-9

Author

Boers, Jorianne ; de Vries, Erik F. J. ; Glaudemans, Andor W. J. M. ; Hospers, Geke A. P. ; Schröder, Carolina P. / Application of PET Tracers in Molecular Imaging for Breast Cancer. In: Current oncology reports. 2020 ; Vol. 22, No. 8.

Harvard

Boers, J, de Vries, EFJ, Glaudemans, AWJM, Hospers, GAP & Schröder, CP 2020, 'Application of PET Tracers in Molecular Imaging for Breast Cancer', Current oncology reports, vol. 22, no. 8, 85. https://doi.org/10.1007/s11912-020-00940-9

Standard

Application of PET Tracers in Molecular Imaging for Breast Cancer. / Boers, Jorianne; de Vries, Erik F. J.; Glaudemans, Andor W. J. M.; Hospers, Geke A. P.; Schröder, Carolina P.

In: Current oncology reports, Vol. 22, No. 8, 85, 06.07.2020.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Boers J, de Vries EFJ, Glaudemans AWJM, Hospers GAP, Schröder CP. Application of PET Tracers in Molecular Imaging for Breast Cancer. Current oncology reports. 2020 Jul 6;22(8). 85. https://doi.org/10.1007/s11912-020-00940-9


BibTeX

@article{699312cf3be449d297a321ed07e58ec9,
title = "Application of PET Tracers in Molecular Imaging for Breast Cancer",
abstract = "PURPOSE OF REVIEW: Molecular imaging with positron emission tomography (PET) is a powerful tool to visualize breast cancer characteristics. Nonetheless, implementation of PET imaging into cancer care is challenging, and essential steps have been outlined in the international {"}imaging biomarker roadmap.{"} In this review, we identify hurdles and provide recommendations for implementation of PET biomarkers in breast cancer care, focusing on the PET tracers 2-[18F]-fluoro-2-deoxyglucose ([18F]-FDG), sodium [18F]-fluoride ([18F]-NaF), 16α-[18F]-fluoroestradiol ([18F]-FES), and [89Zr]-trastuzumab.RECENT FINDINGS: Technical validity of [18F]-FDG, [18F]-NaF, and [18F]-FES is established and supported by international guidelines. However, support for clinical validity and utility is still pending for these PET tracers in breast cancer, due to variable endpoints and procedures in clinical studies. Assessment of clinical validity and utility is essential towards implementation; however, these steps are still lacking for PET biomarkers in breast cancer. This could be solved by adding PET biomarkers to randomized trials, development of imaging data warehouses, and harmonization of endpoints and procedures.",
keywords = "Breast cancer, Molecular imaging, Positron emission tomography, Technical validation, Clinical validation, Clinical utility, POSITRON-EMISSION-TOMOGRAPHY, EANM PROCEDURE GUIDELINES, F-18-FDG PET/CT, FDG-PET/CT, PHASE-II, NEOADJUVANT CHEMOTHERAPY, PATHOLOGICAL RESPONSE, BONE METASTASES, REPEATABILITY, CT",
author = "Jorianne Boers and {de Vries}, {Erik F. J.} and Glaudemans, {Andor W. J. M.} and Hospers, {Geke A. P.} and Schr{\"o}der, {Carolina P.}",
year = "2020",
month = "7",
day = "6",
doi = "10.1007/s11912-020-00940-9",
language = "English",
volume = "22",
journal = "Current oncology reports",
issn = "1523-3790",
publisher = "SPRINGER",
number = "8",

}

RIS

TY - JOUR

T1 - Application of PET Tracers in Molecular Imaging for Breast Cancer

AU - Boers, Jorianne

AU - de Vries, Erik F. J.

AU - Glaudemans, Andor W. J. M.

AU - Hospers, Geke A. P.

AU - Schröder, Carolina P.

PY - 2020/7/6

Y1 - 2020/7/6

N2 - PURPOSE OF REVIEW: Molecular imaging with positron emission tomography (PET) is a powerful tool to visualize breast cancer characteristics. Nonetheless, implementation of PET imaging into cancer care is challenging, and essential steps have been outlined in the international "imaging biomarker roadmap." In this review, we identify hurdles and provide recommendations for implementation of PET biomarkers in breast cancer care, focusing on the PET tracers 2-[18F]-fluoro-2-deoxyglucose ([18F]-FDG), sodium [18F]-fluoride ([18F]-NaF), 16α-[18F]-fluoroestradiol ([18F]-FES), and [89Zr]-trastuzumab.RECENT FINDINGS: Technical validity of [18F]-FDG, [18F]-NaF, and [18F]-FES is established and supported by international guidelines. However, support for clinical validity and utility is still pending for these PET tracers in breast cancer, due to variable endpoints and procedures in clinical studies. Assessment of clinical validity and utility is essential towards implementation; however, these steps are still lacking for PET biomarkers in breast cancer. This could be solved by adding PET biomarkers to randomized trials, development of imaging data warehouses, and harmonization of endpoints and procedures.

AB - PURPOSE OF REVIEW: Molecular imaging with positron emission tomography (PET) is a powerful tool to visualize breast cancer characteristics. Nonetheless, implementation of PET imaging into cancer care is challenging, and essential steps have been outlined in the international "imaging biomarker roadmap." In this review, we identify hurdles and provide recommendations for implementation of PET biomarkers in breast cancer care, focusing on the PET tracers 2-[18F]-fluoro-2-deoxyglucose ([18F]-FDG), sodium [18F]-fluoride ([18F]-NaF), 16α-[18F]-fluoroestradiol ([18F]-FES), and [89Zr]-trastuzumab.RECENT FINDINGS: Technical validity of [18F]-FDG, [18F]-NaF, and [18F]-FES is established and supported by international guidelines. However, support for clinical validity and utility is still pending for these PET tracers in breast cancer, due to variable endpoints and procedures in clinical studies. Assessment of clinical validity and utility is essential towards implementation; however, these steps are still lacking for PET biomarkers in breast cancer. This could be solved by adding PET biomarkers to randomized trials, development of imaging data warehouses, and harmonization of endpoints and procedures.

KW - Breast cancer

KW - Molecular imaging

KW - Positron emission tomography

KW - Technical validation

KW - Clinical validation

KW - Clinical utility

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - EANM PROCEDURE GUIDELINES

KW - F-18-FDG PET/CT

KW - FDG-PET/CT

KW - PHASE-II

KW - NEOADJUVANT CHEMOTHERAPY

KW - PATHOLOGICAL RESPONSE

KW - BONE METASTASES

KW - REPEATABILITY

KW - CT

U2 - 10.1007/s11912-020-00940-9

DO - 10.1007/s11912-020-00940-9

M3 - Review article

C2 - 32627087

VL - 22

JO - Current oncology reports

JF - Current oncology reports

SN - 1523-3790

IS - 8

M1 - 85

ER -

ID: 129202951